Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. - Wikidata - wikimedia - TriplyDB

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.

http://www.wikidata.org/entity/Q36000813

about

Intravital imaging reveals new ancillary mechanisms co-opted by cancer cells to drive tumor progression Targeting ECM Disrupts Cancer Progression GEMMs as preclinical models for testing pancreatic cancer therapies The role of integrins in TGFβ activation in the tumour stroma Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene Structural ECM components in the premetastatic and metastatic niche.Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.VEGF blockade enhances the antitumor effect of BRAFV600E inhibition.ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth.Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection.The role of hypoxia in pancreatic cancer: a potential therapeutic target?Dynamic contrast-enhanced MRI of the microenvironment of pancreatic adenocarcinoma xenografts.Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium.Lysyl Oxidase Isoforms and Potential Therapeutic Opportunities for Fibrosis and Cancer.A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1.Genomic analyses identify molecular subtypes of pancreatic cancer.Force Matters: Biomechanical Regulation of Cell Invasion and Migration in Disease.The 2016 John J. Abel Award Lecture: Targeting the Mechanical Microenvironment in Cancer.Lysyl Oxidase: Its Diversity in Health and Diseases.Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy.Inhibition of Lysyl Oxidase and Lysyl Oxidase-Like Enzymes Has Tumour-Promoting and Tumour-Suppressing Roles in Experimental Prostate Cancer.Lymph node metastasis and the physicochemical micro-environment of pancreatic ductal adenocarcinoma xenografts.Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease.α5β1-Integrin promotes tension-dependent mammary epithelial cell invasion by engaging the fibronectin synergy site.Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.From transformation to metastasis: deconstructing the extracellular matrix in breast cancer.Transient targeting of the pancreatic cancer stroma as a 'fine-tuned' anti-tumor and anti-metastatic therapy.Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology.The fibrotic tumor stroma.Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?The interplay between extracellular matrix remodelling and kinase signalling in cancer progression and metastasis.Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy.Tissue Force Programs Cell Fate and Tumor Aggression.Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway.Charting the unexplored extracellular matrix in cancer.Targeting the tumour stroma to improve cancer therapy.Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside.

P2860

Q26745311-3141FDEC-9C89-4157-A7E0-3099BBD20846 Q26779300-90BE951B-7CB4-45A6-8E26-C0BA0482092F Q26781848-D45EBB4F-D853-4957-A106-ED7A7242FD0E Q28068373-3B6B5031-CFC3-4A07-9B31-448CC9B177B5 Q33587066-E3B2E4E1-D6FF-4715-8AC6-9CF5321DB04B Q33688524-4DECA087-1C6D-4114-8673-6349C2123FFA Q33779491-5089EF2D-A0CC-4F45-9C65-6F076404FF64 Q34521147-E3C645B7-19F8-49B6-82F8-F1B80425EB1B Q37362619-055400BF-E23F-4706-BF26-78D355B79F53 Q37618011-1855F7BA-57CF-4C23-9358-59DA650BE489 Q37618014-0F9696A2-1B10-4B42-A029-F6D68E62BCBA Q37687298-D867705E-C399-4D3E-894E-086DFEC86647 Q37689086-7BC580B7-7381-4661-AA74-A3B834BD4B4D Q38631404-6AC8394C-0520-426D-B5DA-3C4837C6FA19 Q38665197-6258D558-E841-4768-8FA5-3985C650E950 Q38697619-31FC4606-A9B7-4EA2-9685-B05ABABCD00C Q38723997-DB49431C-C68D-4C58-8035-54B50EFB3CBD Q38728079-BA975F58-3F6F-4F9F-918B-2B599D0C71B0 Q38791499-17097598-DF3C-4E2D-A845-97F859C42C17 Q38801418-C0FD5095-0723-4D1C-8AE4-94AC06DB53D3 Q38981265-5C09AA0B-8761-4F95-9FA1-3F91202B06C9 Q39253646-40C10A0F-DDB8-4B98-9478-23EE91E0392F Q39268764-11E937AD-17CC-4EDA-BC5E-13B2463E6C7F Q40068242-299A6B0C-60CF-4D05-8BE4-34B476FD78EF Q41471434-4CF16712-E6B6-4BE6-9BE2-CBA26E98F82F Q42416539-EDF7431B-0331-478E-B29A-3F4471DFC490 Q44868839-3D18DAC1-4512-415B-B504-CBC8F448202F Q45987365-B52E5534-2C75-4B94-A693-A71B74F552CC Q46214350-12D04CD1-FBD8-4FE3-BCCA-4CC65E71ECB0 Q47097259-3F096D3F-A2C4-426E-8507-34D6400F5737 Q47134459-61F6A663-48F7-413E-90EC-4497B8C9AEC9 Q47205727-7813C7A9-ECA5-411C-842F-5FB353E06549 Q48219198-E9F0E936-33AA-4660-99A0-85855DBF9EF9 Q48247148-89F4FB12-CCDE-46AD-9D69-E31F8661AF46 Q48253065-B861FB94-F6A4-4264-ABE8-C4654A0C4220 Q50077270-4117F768-CA12-435B-86D6-DD59A18E9AFF Q50218607-F6A165B7-7BF5-49AF-841F-C37D422944AD Q52315803-915502E1-B0E6-4229-85F7-CB0A7080B3F6 Q52322982-522A7275-B284-4443-B182-1B8F06F192C8 Q52615294-42C60CB5-6AB4-4F28-B685-3287A8F28BE3

P2860

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.

http://www.wikidata.org/entity/Q36000813

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Targeting the LOX/hypoxia axis ...... is and enhances drug efficacy.

@ast

Targeting the LOX/hypoxia axis ...... is and enhances drug efficacy.

@en

type

label

Targeting the LOX/hypoxia axis ...... is and enhances drug efficacy.

@ast

Targeting the LOX/hypoxia axis ...... is and enhances drug efficacy.

@en

prefLabel

Targeting the LOX/hypoxia axis ...... is and enhances drug efficacy.

@ast

Targeting the LOX/hypoxia axis ...... is and enhances drug efficacy.

@en

P1433

Q36000813-A779E645-C5C6-4752-88FE-E148FDC34E26

P1476

Q36000813-4678D359-8979-4298-AD78-C5D8BE3CCD13

P2093

Q36000813-1C41926E-93FE-44F3-BDB5-88D552DAB9A3

Q36000813-2F25BEE3-866D-473E-9307-2429C3509B03

Q36000813-2F5F5C1F-3958-4483-B69F-3CBAD1232CCD

Q36000813-48A42AB4-51B2-45A3-93D3-56DAE9C2BBE8

Q36000813-606352E9-7C9F-471E-BE09-9CD354A1B0C9

Q36000813-80D42FBC-90DC-4C18-8187-61A5E4682064

Q36000813-8CE2A506-B2C7-4267-ADFB-B3D4CFE14FCF

Q36000813-9922454B-AE8D-4FD1-B756-3070EFE3040D

Q36000813-C2C6574D-DDC6-402E-8812-F3BC4CDF2FFB

Q36000813-C4A0675C-C009-4E46-AE3B-46CB922EC2AD

P2860

Q36000813-0C7118EE-A350-48C5-B49C-D6E409142C26

Q36000813-1ECC2AF9-6359-4C95-A4FF-533063EB1DA2

Q36000813-2106347A-A685-4E56-870C-AA1FCCF6556B

Q36000813-2184E21C-8C1B-48F9-A68A-DF0F7F6EBEAB

Q36000813-258D6F94-CD37-4DAE-A46D-02EA89130F1D

Q36000813-2636117E-4D11-483C-82DD-A56F78A17459

Q36000813-28579834-4A55-4F92-92BD-8309A454822A

Q36000813-28D795A2-FFF6-451F-8C70-2B901CAC565A

Q36000813-29AE0270-4BC0-49EC-A02B-FE17A075A69D

Q36000813-2A0B3CB7-DB82-40CB-93C2-55FC45723BCB

P304

Q36000813-34061165-F6A4-47EA-971F-D010D2AAD622

P31

Q36000813-D923F4D6-9CD0-4144-9168-19BDEF0D02E8

P356

Q36000813-BA916A63-1F7F-40F8-A7AD-43C0E089A503

P433

Q36000813-7FD76ACD-7F57-4A6C-83E7-16AEDC42CB9F

P478

Q36000813-B934A7B0-0239-4CCA-B235-71F83AEFBD38

P50

Q36000813-01456A64-86F7-44DA-B16F-1BAC4CAA361F

Q36000813-0A4C6162-58F1-4F8D-9CF2-2F11685DA7FA

Q36000813-3A21AEEA-47AE-4DC9-BEA5-E95C8C4EF681

Q36000813-43C0889D-F0F3-4B77-B9A6-10F557BB080F

Q36000813-587925CB-9571-42A1-9986-CD0D194E00E1

Q36000813-92226A77-AA3F-403E-98CF-884AC64B20C5

Q36000813-AB2495D1-9D0D-428C-B9EE-BDC2575F9762

Q36000813-D36752BA-A2FF-42F7-BD03-4BE5587495D7

Q36000813-D8C407FC-8FA6-4321-9244-19DF9E5E246A

Q36000813-E90BA898-21BE-488C-9574-A44128C9CE7B

P577

Q36000813-C012AB8E-878C-4B0D-A5C0-F634364FD0B3

P5875

Q36000813-E0FEEDC9-C9D0-4B23-8835-6D003A048734

P698

Q36000813-AA29144A-2492-4473-AA1F-A69EE7A63B80

P921

Q36000813-7C44F9D2-6DFA-4F51-895C-2308E199DF9A

P932

Q36000813-0D1E4584-89CF-4048-BF36-FBBB912ECDC8

P356

P1433

EMBO Molecular Medicine

P1476

Targeting the LOX/hypoxia axis ...... sis and enhances drug efficacy

@en

P2093

Amy Au

http://www.w3.org/2001/XMLSchema#string

Bryan W Miller

http://www.w3.org/2001/XMLSchema#string

Christopher Ross Carter

http://www.w3.org/2001/XMLSchema#string

Colin McKay

http://www.w3.org/2001/XMLSchema#string

Colin Steele

http://www.w3.org/2001/XMLSchema#string

David Chang

http://www.w3.org/2001/XMLSchema#string

Ewan McGhee

http://www.w3.org/2001/XMLSchema#string

Grazia Saturno

http://www.w3.org/2001/XMLSchema#string

Lynn McGarry

http://www.w3.org/2001/XMLSchema#string

Nigel B Jamieson

http://www.w3.org/2001/XMLSchema#string

P2860

A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche

Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth

Lysyl oxidase is essential for hypoxia-induced metastasis

Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis

The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Adjusting batch effects in microarray expression data using empirical Bayes methods

P304

1063-1076

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.15252/EMMM.201404827

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Jennifer P. Morton

Janine T. Erler

Caroline J Springer

P577

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280033040

http://www.w3.org/2001/XMLSchema#string

P698

26077591

http://www.w3.org/2001/XMLSchema#string

P921

P932

4551344

http://www.w3.org/2001/XMLSchema#string